Unlike U0126, which only attenuated the expression of BRN2, 666-15 significantly impaired FTT-induced neuronal like morphology, attenuated FTT-induced upregulation of ASCL1, BRN2, and MYT1L, and reduced the percentage of MAP2+ cells (Supplementary Fig. S6C–F), suggesting that CREB signaling might also contribute to  FTT-induced neuronal reprogramming of GBM cells. The gene discussed is MAP2; the disease is glioblastoma.